Metastatic Triple-Negative Breast Cancer — The Selection and Sequencing of Therapy
Dr Ana C Garrido-Castro and Prof Peter Schmid review patient cases and provide insights regarding the treatment of metastatic triple-negative breast cancer. CME information and select publications here.
--------
58:41
--------
58:41
Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management
Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management. CME information and select publications here.
--------
54:23
--------
54:23
Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event Management
Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer therapies. CME information and select publications here.
--------
57:47
--------
57:47
Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer. CME information and select publications here.
--------
23:19
--------
23:19
Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 1
Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas review available efficacy and safety data guiding the optimal integration of oral SERDs into clinical practice. CME information and select publications here.
Brasil